Designed for individuals who are incorporating GLP-1 medications into their routines, the new menu is intended to empower guests with great tasting, nutritional choices that complement their unique needs
Figure from Rossing et al NDT 2023 Primary Outcome This was a composite of time of first occurrence of: Onset of kidney failure (persistent eGFR 28 days or initiation of long-term KRT, kidney transplantation) Persistent 50% reduction in eGFR from baseline Death from kidney or CV causes Secondary Outcomes Confirmatory secondary outcomes were analyzed hierarchically
Dosage form optimization: Controlled-release formulations enabling once-weekly oral administration Indication expansion: NASH, Alzheimers disease, cardiovascular protection Conclusion: A game-changing Molecule Design Orforglipron represents a triumph in small molecule drug designit demonstrates that clever chemical structure design can break through the dominance of biologics
Traditional GLP-1 therapies are synonymous with gastrointestinal distress, including nausea, vomiting, diarrhea, and constipation